Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP

Ron D Jachimowicz; Wolfram Klapper; Gunther Glehr; Horst Müller; Heinz Haverkamp; Christoph Thorns; Martin Leo Hansmann; Peter Möller; Harald Stein; Thorsten Rehberg; Bastian von Tresckow; H C Reinhardt; Peter Borchmann; Fong Chun Chan; Rainer Spang; David W Scott; Andreas Engert; Christian Steidl; Michael Altenbuchinger; Andreas Rosenwald

doi:10.1038/s41375-021-01314-1

Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP

Leukemia. 2021 Dec;35(12):3589-3593. doi: 10.1038/s41375-021-01314-1. Epub 2021 Jun 10.

Authors

Ron D Jachimowicz^#^{1

2

3

4}, Wolfram Klapper^#⁵, Gunther Glehr⁶, Horst Müller⁷, Heinz Haverkamp⁷, Christoph Thorns⁸, Martin Leo Hansmann⁹, Peter Möller¹⁰, Harald Stein¹¹, Thorsten Rehberg⁶, Bastian von Tresckow^{7

12}, H C Reinhardt¹², Peter Borchmann⁷, Fong Chun Chan¹³, Rainer Spang⁶, David W Scott¹³, Andreas Engert⁷, Christian Steidl¹³, Michael Altenbuchinger^{6

14}, Andreas Rosenwald¹⁵

Affiliations

¹ Department I of Internal Medicine; German Hodgkin Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. [email protected].
² Max Planck Research Group Mechanisms of DNA Repair, Max Planck Institute for Biology of Ageing, Cologne, Germany. [email protected].
³ Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne, Cologne, Germany. [email protected].
⁴ Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany. [email protected].
⁵ Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany.
⁶ Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.
⁷ Department I of Internal Medicine; German Hodgkin Study Group, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
⁸ Department of Pathology, Marien-Hospital Hamburg, Hamburg, Germany.
⁹ Department of Pathology, University Hospital Frankfurt, Frankfurt, Germany.
¹⁰ Department of Pathology, University Hospital Ulm, Ulm, Germany.
¹¹ Pathodiagnostik, Berlin, Germany.
¹² Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University Duisburg-Essen, German Cancer Consortium (DKTK partner site Essen), Essen, Germany.
¹³ British Columbia Cancer Agency, Vancouver, BC, Canada.
¹⁴ Research Group Computational Biology, University of Hohenheim, Stuttgart, Germany.
¹⁵ Institute of Pathology, University of Würzburg, and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bleomycin / therapeutic use
Chemokine CCL17 / genetics
Chemokine CCL17 / metabolism
Cyclophosphamide / therapeutic use
Doxorubicin / therapeutic use
Etoposide / therapeutic use
Female
Gene Expression Profiling / methods
Hodgkin Disease / drug therapy*
Hodgkin Disease / genetics
Hodgkin Disease / pathology*
Humans
Ki-1 Antigen / genetics
Ki-1 Antigen / metabolism
Male
Middle Aged
Neoplasm Staging
Predictive Value of Tests
Prednisone / therapeutic use
Procarbazine / therapeutic use
Receptor, Platelet-Derived Growth Factor alpha / genetics
Receptor, Platelet-Derived Growth Factor alpha / metabolism
Survival Rate
Transcriptome
Treatment Outcome
Vincristine / therapeutic use
Young Adult

Substances

CCL17 protein, human
Chemokine CCL17
Ki-1 Antigen
Bleomycin
Procarbazine
Vincristine
Etoposide
Doxorubicin
Cyclophosphamide
Receptor, Platelet-Derived Growth Factor alpha
Prednisone

Supplementary concepts

BEACOPP protocol